Cargando…

Protein expression patterns of cell cycle regulators in operable breast cancer

BACKGROUND-AIM: To evaluate the prognostic role of elaborate molecular clusters encompassing cyclin D1, cyclin E1, p21, p27 and p53 in the context of various breast cancer subtypes. METHODS: Cyclin E1, cyclin D1, p53, p21 and p27 were evaluated with immunohistochemistry in 1077 formalin-fixed paraff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zagouri, Flora, Kotoula, Vassiliki, Kouvatseas, George, Sotiropoulou, Maria, Koletsa, Triantafyllia, Gavressea, Theofani, Valavanis, Christos, Trihia, Helen, Bobos, Mattheos, Lazaridis, Georgios, Koutras, Angelos, Pentheroudakis, George, Skarlos, Pantelis, Bafaloukos, Dimitrios, Arnogiannaki, Niki, Chrisafi, Sofia, Christodoulou, Christos, Papakostas, Pavlos, Aravantinos, Gerasimos, Kosmidis, Paris, Karanikiotis, Charisios, Zografos, George, Papadimitriou, Christos, Fountzilas, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552326/ https://www.ncbi.nlm.nih.gov/pubmed/28797035 http://dx.doi.org/10.1371/journal.pone.0180489

Ejemplares similares

Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial
por: Fountzilas, George, et al.
Publicado: (2013)

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting
por: Fountzilas, George, et al.
Publicado: (2016)

alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies
por: Koletsa, Triantafyllia, et al.
Publicado: (2014)

Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel
por: Fountzilas, George, et al.
Publicado: (2012)

Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
por: Fountzilas, George, et al.
Publicado: (2012)

Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study
por: Koutras, Angelos, et al.
Publicado: (2018)

MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer
por: Gogas, Helen, et al.
Publicado: (2016)

Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy
por: Timotheadou, Eleni, et al.
Publicado: (2017)

Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study
por: Koutras, Angelos, et al.
Publicado: (2015)

Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy—A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study
por: Spathas, Nikolaos, et al.
Publicado: (2022)

Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early‐stage breast cancer patients treated with anthracycline‐based adjuvant chemotherapy
por: Tsiatas, Marinos, et al.
Publicado: (2018)

A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)
por: Pentheroudakis, George, et al.
Publicado: (2014)

Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer
por: Fountzilas, Elena, et al.
Publicado: (2019)

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
por: Fountzilas, George, et al.
Publicado: (2012)

Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens
por: Kourea, Helen P., et al.
Publicado: (2022)

Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative
por: Fountzilas, Elena, et al.
Publicado: (2020)

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
por: Fountzilas, George, et al.
Publicado: (2013)

Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials
por: Kotoula, Vassiliki, et al.
Publicado: (2015)

Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab
por: Mountzios, G, et al.
Publicado: (2019)

Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial
por: Goussia, Anna, et al.
Publicado: (2018)

Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study
por: Papaxoinis, George, et al.
Publicado: (2015)

The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial
por: Linardou, Helena, et al.
Publicado: (2012)

Adjusting Breast Cancer Patient Prognosis with Non-HER2-Gene Patterns on Chromosome 17
por: Kotoula, Vassiliki, et al.
Publicado: (2014)

In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients
por: Vassilakopoulou, Maria, et al.
Publicado: (2014)

Differential Expression of the Insulin-Like Growth Factor Receptor among Early Breast Cancer Subtypes
por: Mountzios, Giannis, et al.
Publicado: (2014)

A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study
por: Papadimitriou, Christos A, et al.
Publicado: (2011)

Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
por: Fountzilas, George, et al.
Publicado: (2014)

Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy
por: Kostopoulos, Ioannis, et al.
Publicado: (2009)

Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab
por: Economopoulou, Panagiota, et al.
Publicado: (2019)

Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group
por: Psyrri, Amanda, et al.
Publicado: (2017)

Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer
por: Fountzilas, Elena, et al.
Publicado: (2018)

MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer
por: Fountzilas, George, et al.
Publicado: (2009)

Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes
por: Kotoula, Vassiliki, et al.
Publicado: (2016)

Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG)
por: Zarkavelis, George, et al.
Publicado: (2019)

Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
por: Murray, Samuel, et al.
Publicado: (2012)

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
por: Pectasides, Dimitrios, et al.
Publicado: (2012)

Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study
por: Stavridi, Flora, et al.
Publicado: (2016)

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
por: Pentheroudakis, George, et al.
Publicado: (2013)

Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group
por: Bafaloukos, D, et al.
Publicado: (2004)

Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research
por: Kotoula, Vassiliki, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3qpo49fqctcgin94hj26dcj659